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Abstract
Background: Graves’ disease is the commonest cause of thyrotoxicosis whilst thyrotropin (TSH)-producing pituitary
adenomas (thyrotropinomas, TSHomas) are very rare and account for just 1–2% of all pituitary adenomas. Coexistence
of a TSHoma and Graves’ disease has been very rarely reported. Here, we report a case of a patient whose initial
presentation with primary thyrotoxicosis due to Graves’ disease, was subsequently followed by a relapse of
thyrotoxicosis due to a probable TSHoma.
Case: A sixty-eight year old woman was referred to our department with classical features of thyrotoxicosis.
Initial biochemistry confirmed hyperthyroxinaemia [free thyroxine (fT4) 20.4 pmol/L (reference range 7.0–16.0)]
and a suppressed TSH [< 0.02mIU/L (0.50–4.20)]. A technetium pertechnetate uptake scan was consistent with
Graves’ Disease. She was treated with carbimazole for 18months and remained clinically and biochemically euthyroid.
After stopping carbimazole her fT4 started to rise but TSH remained normal. Laboratory assay interference was excluded.
A TRH stimulation test demonstrated a flat TSH response and pituitary MRI revealed a microadenoma. Remaining pituitary
hormones were in the normal range other than a slightly raised IGF-1. An 11C-methionine PET/CT scan coregistered with
volumetric MRI (Met-PET-MRICR) demonstrated high tracer uptake in the left lateral sella region suggestive of a functioning
adenoma. The patient declined surgery and was unable to tolerate cabergoline or octreotide. Thereafter, she has elected
to pursue a conservative approach with periodic surveillance.
Conclusion: This is a very unusual case of thyrotoxicosis caused by two different processes occurring in the same patient.
It highlights the importance of considering dual pathology when previously concordant thyroid function tests become
discordant. It also highlights a potential role of Met-PET-MRICR in the localisation of functioning pituitary tumours.
Keywords: Graves’ disease, TSH-secreting pituitary adenoma, TSHoma, Thyrotropinoma, Coexistent primary and
secondary hyperthyroidism
Background
Graves’ disease is the most common cause of thyrotoxi-
cosis [1]. It occurs when autoantibodies (TRAb) bind to
thyroid stimulating hormone (TSH) receptors driving
unregulated production of thyroid hormones [triiodo-
thyronine (T3) and thyroxine (T4)] that is independent
of pituitary TSH. The diagnosis is based on the presence
of typical features of thyrotoxicosis (± pathognomonic
signs, e.g. dysthyroid eye disease), raised free thyroid
hormones (fT3 and fT4) with suppressed TSH (trad-
itionally < 0.1 mU/L), high TRAb titres and/or character-
istic increased diffuse uptake on thyroid scintigraphy
(using iodine or technetium).
In contrast, TSH producing pituitary adenomas
(TSHomas, thyrotropinomas) are a much rarer cause of
thyrotoxicosis [2]. They are associated with a biochemical
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pattern of central/secondary hyperthyroidism (ele-
vated T3/T4 with a non-suppressed TSH), which is
distinct from that of Graves’ disease and other
causes of primary hyperthyroidism. The diagnosis is
often challenging, reflecting significant variation in
clinical manifestations, difficulty in confirming genu-
ine hyperthyroxinaemia with non-suppressed TSH,
and the increasing recognition that a significant pro-
portion of TSHomas are microadenomas which are
not always readily visualized on magnetic resonance
imaging (MRI) [3]. A 2014 retrospective study of all
histopathologically proven TSHomas over a 10 year
period from a single centre confirmed this wide
spectrum of clinical presentations with 34% present-
ing with visual field disturbance, 25% with thyrotoxi-
cosis, 13% with secondary amenorrhoea and 9% with
headaches [4].
The distinction between primary and secondary hyper-
thyroidism is important as the treatment is different for
each condition. For example, treating thyrotoxicosis sec-
ondary to a TSHoma with antithyroid medications,
radioactive iodine or thyroid surgery, as one would with
primary thyroid disorders, can reduce the negative feed-
back on a TSHoma and promote tumour growth and
potentially worsen thyrotoxicosis [4].
There are, however, a small number of case reports of
both Graves’ disease and a TSHoma co-existing [5–13]
This combination poses a number of diagnostic and
therapeutic challenges, including localising microadenomas
when MRI is indeterminate. In recent years functional im-
aging with 11-C-methionine PET-CT for pituitary aden-
omas has been employed to help diagnose and accurately
localise functional pituitary tumours [14–16]
Here, we describe a patient initially diagnosed with
primary thyrotoxicosis due to Graves’ disease, who sub-
sequently developed secondary thyrotoxicosis from a
probable TSHoma. We also report the use of 11C-me-
thionine positron emission tomography to aid the local-
isation of this condition.
Case presentation
A 68-year-old lady was originally referred to our endo-
crine service in 2011 with a diagnosis of thyrotoxicosis.
Her thyroid function tests panel are shown in Table 1.
She was asymptomatic and appeared clinically euthyroid
with a resting heart rate of 68 beats per minute and an
unremarkable head and neck exam. Her baseline ECG
was normal. She had no known family history of any
thyroid disorders.
A technetium-99 m pertechnetate thyroid uptake scan
demonstrated homogenous diffuse tracer uptake in both
lobes in keeping with a diagnosis of Graves’ disease
(Fig. 1.). Sex hormone binding globulin was 92 nmol/l
(27–128).
She was started on carbimazole and remained clinic-
ally and biochemically euthyroid for the following 18
months (Table 1).
Carbimazole was stopped in January 2013 and the pa-
tient was followed in our clinic with serial thyroid func-
tion tests. She remained asymptomatic but her blood
tests over the next 2 years demonstrated a discordant
pattern – a persistently elevated free T4 with a TSH
level inappropriately in the normal range (Table 1). She
was clinically euthyroid without a goitre.
The same pattern was confirmed on several different
laboratory platforms and assay interference was formally
excluded. TFTs on the 2 step Delfia platform showed a
free T4 of 26.8 pmol/L (9.0–20), a free T3 of 8.5 nmol/L
(3.0–7.5) and a TSH of 0.74 mU/L (0.4–4.0) while TFTs
on the 1 step Centaur platform showed a free T4 of
23.9 pmol/L (10.0–19.8), a free T3 of 6.7 pmol/L (3.5–
6.5) and a TSH of 0.76 mU/L (0.35–5.50). The alpha
subunit was in the normal range [0.9 IU/L (RR < 1.0)],
but a thyrotropin releasing hormone (TRH) stimulation
test demonstrated a flat TSH response (TSH 0.73 / 0.72
/ 0.70 mU/L at 0, 20 and 60 min respectively). A pituit-
ary blood profile was unremarkable aside from a mildly
elevated serum insulin-like growth factor 1 level (1.2 ×
upper limit of normal) (Table 2). An oral glucose
Table 1 Thyroid Function Tests & Endocrine Treatment
Date Endocrine Treatment Free T4
(7.0–16.0 pmol/L)
TSH
(0.5–4.2 mU/L)
July 2011 CBZ commenced 20.4 < 0.02
November 2011 CBZ 5 mg/day 9.9 3.11
November 2012 CBZ 5 mg/day 14.6 1.65
January 2013 CBZ discontinued
March 2013 nil 17.7 0.82
May 2013 nil 20.4 0.63
July 2014 nil 21.5 0.67
October 2015 nil 20.1 0.77
Serial thyroid function tests prior to, during, and following discontinuation of antithyroid drug therapy
Key: CBZ carbimazole, T4 thyroxine, TSH thyroid stimulating hormone
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tolerance test (OGTT) was performed as a growth hor-
mone suppression test. This showed borderline growth
hormone suppression with a nadir of 0.43 ng/mL
(Table 3). The patient had no clinical features of acro-
megaly. A T3 suppression test was considered but fol-
lowing discussion with the patient she decided against
this.
A pituitary MRI scan showed asymmetric enlargement
of the gland, raising the possibility of a left-sided pituit-
ary microadenoma (Fig. 2). An 11C-methionine PET/CT
scan was performed and coregistered with a volumetric
[fast spoiled gradient recall (FSPGR) MRI scan (Met-
PET-MRICR)]. This demonstrated focal increased tracer
uptake at the site of the suspected microadenoma (Figs. 3
and 4). Her biochemical and radiological findings were
therefore consistent with the diagnosis of a TSH-
secreting pituitary adenoma. The slightly raised IGF-1
and borderline suppression of GH on OGTT also raised
the possibility of GH co-secretion. The patient was tried
on a somatostatin analogue (SSA) first then a dopamine
agonist but did not tolerate either (due to gastrointes-
tinal side-effects). She declined pituitary surgery. She is
currently managed with a beta-adrenergic blocker and is
clinically euthyroid.
Discussion and conclusion
This is an unusual case of a patient with dual pathology:
primary thyrotoxicosis due to Graves’ disease (GD) and
secondary hyperthyroidism due to a probable TSHoma.
Careful interpretation of laboratory and radiological
Fig. 1 Thyroid uptake scan. Thyroid uptake scan (technetium-99 m
pertechnetate) demonstrating homogenous tracer uptake in
both lobes
Table 2 Pituitary Blood Profile
08/08/2016 Ref. range
AM Cortisol (nmol/L) 373 185–624
FSH (mIU/mL) 98.5 30–120
LH (mIU/mL) 36.2 15–62
Basal Growth Hormone (ng/mL) 0.96
IGF-1 (ng/mL) 201 37–166
Prolactin (mIU/L) 247 58–416
Repeat pituitary blood profile
Key: FSH follicle-stimulating hormone, LH luteinizing hormone, IGF-1 insulin-like
growth factor 1
Table 3 Oral Glucose Tolerance Test
Oral Glucose Tolerance Test
Time (minutes) Blood Glucose (mmol/L) Growth Hormone (ng/ml)
0 5.2 7.07
30 9.0 1.63
60 9.0 0.78
90 5.2 0.57
120 4.5 0.43
150 0.45
A summary of the existing case reports of patients with both Graves’ disease
and a TSHoma
GD Graves’ Disease, CBZ Carbimazole, TSS Transsphenoidal surgery, PTU
Propylthiouracil, MMI Methimazole
Fig. 2 MRI Pituitary. MRI Pituitary showing enlargement of the left
side of the pituitary - findings suspicious for a
pituitary microadenoma
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findings allowed both conditions to be identified in a
timely manner, and guided choice of therapy.
In cases of primary thyrotoxicosis (high free T4 and
suppressed TSH) current guidelines suggest measuring
anti-TSH receptor antibody (TRab) levels at an early
stage [17]. TRab levels are positive in 90 [18]–99% [19]
of cases of GD depending on the generation of assay
used. In contrast, thyroid peroxidase (TPO) antibodies
are only positive in 75–80% of cases of GD [20]. Thyroid
scintigraphy and/or ultrasound may provide additional
diagnostic information as the most common causes of pri-
mary hyperthyroidism, Graves’ disease and toxic multinod-
ular goitre, have characteristic features on imaging [21].
For cases of suspected central (secondary) hyperthy-
roidism it is essential to exclude laboratory assay inter-
ference before proceeding with further investigations.
Circulating heterophilic antibodies or human anti-
animal immunoglobulins may cause spurious TSH re-
sults. Several approaches can be employed to detect such
interference. At the simplest level, the demonstration of
discordant results when TSH is measured using two dif-
ferent assay platforms is reasonable evidence of assay
interference. However, other techniques [e.g. TSH meas-
urement following serial dilution or polyethylene glycol
(PEG) precipitation] provide more robust assessments of
TSH integrity [22].
Similarly, free thyroid hormone levels may be artifac-
tually raised and consideration should also be given to
excluding causes of FT4 (±FT3) assay interference.
Once genuine hyperthyroxinaemia with non-suppressed
TSH has been confirmed, investigations are targeted to-
wards differentiating between a TSH-secreting pituitary
adenoma and thyroid hormone resistance due to a loss-of-
function mutation in the human THRB gene. Classically,
TSHomas exhibit a blunted response to TRH stimulation,
elevated sex hormone binding globulin (SHBG), raised
alpha subunit (ASU), and reduction in thyroid hormone
levels in response to depot SSA therapy. However, these
findings are not universal. Our patient demonstrated no
change in TSH following TRH injection, but ASU was
within normal limits. She was unable to tolerate SSA.
Fig. 3 11C-methionine PET/CT coregistered with volumetric MRI. 11C-methionine PET/CT coregistered with volumetric MRI Cornonal and axial
views showing a focus of increased tracer uptake in the left side of the sella (yellow arrows) corresponding to the site of a possible
microadenoma on MRI (white arrows)
Fig. 4 11C-methionine PET/CT coregistered with volumetric MRI.
Coronal view
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Pituitary imaging with T1- and T2-weighted MRI re-
mains the gold standard for identifying pituitary aden-
omas [23]. However, interpretation of pituitary MRI
scans can be complicated by the high rate of pituitary
incidentalomas in the general population. One large
study found pituitary adenomas (mostly microadenomas)
in 10.6% of subjects at autopsy [23]. This was in a group
of patients who were not suspected of having pituitary
disease while they were alive.
Whilst TSHomas are very rare they co-secrete other
pituitary hormones in a high proportion of cases. This
most commonly involves co-secretion of growth hor-
mone (16% of cases) and prolactin (10%) [24]. In our
case the elevated levels of IGF-1 raised the possibility of
growth hormone hypersecretion. There were no signs of
acromegaly and an oral glucose tolerance test (OGTT)
demonstrated growth hormone suppression to 0.43 ng/
mL. While this could possibly represent very low grade
autonomous growth hormone secretion we felt this was
unlikely given the lack of any clinical features of acro-
megaly. In a case with borderline results it is also worth
noting that GH nadir levels are often higher in females
than in males [25].
In recent years, functional pituitary imaging has been
proposed as a useful tool for identifying the site(s) of a
pituitary adenoma in patients with inconclusive MRI
findings [26]. 11Carbon-methionine is an amino acid
based PET tracer which, unlike the glucose-based tracer
18F-fluorodeoxyglucose, is preferentially taken up by
normal pituitary tissue [27] with relatively low uptake by
background brain tissue. Coregistration of 11C-Methio-
nine PET/CT and volumetric (e.g FSPGR) MRI may be
superior to MRI alone in localizing some pituitary
microadenomas [16, 28, 29]
Inferior petrosal sinus sampling (IPSS) is often consid-
ered the gold standard investigation for the diagnosis of
functional pituitary tumours. This is an invasive test that
requires significant technical expertise. While more data
is needed on the utility of Met-PET-MRICR there is
some evidence to suggest it is a highly sensitive non-
invasive test that could be considered as an alternative
to IPSS [30]. In our case, although MRI raised suspicion
of a left-side abnormality, no definite adenoma was seen.
However, Met-PET-MRICR confirmed focal tracer up-
take corresponding to this site.
IPSS and a pituitary biopsy may have been useful in-
vestigations to confirm the diagnosis but they need to be
considered in the clinical context. In this case they were
both felt to be unnecessarily invasive in an asymptomatic
patient.
Literature review
Whilst the dual diagnosis of primary and central thyro-
toxicosis in the same patient is recognised to be exceed-
ingly rare, some case reports of this pattern have been
published in recent years (Table 4). The majority of
these cases were in females (80%) all aged between 25
and 53 years old. Interestingly the dual diagnosis was
confirmed within 3 years of the original diagnosis in all
cases. This has led to a number of theories in the litera-
ture suggesting that treatment of the original condition
may in fact promote the development of the subsequent
condition. In the cases where Graves’ disease was diag-
nosed initially (40%) one hypothesis is that treatment
with antithyroid medications may promote the growth
of a TSHoma, due to the positive feedback system, so
accelerating the presentation [6]. Conversely a number
of theories have been proposed to explain why Graves’s
disease may present following treatment of a TSHoma.
Kageyama et al. demonstrated that anti-thyrotropin re-
ceptor antibody levels were significantly elevated post re-
moval of a TSHoma in a 21 year old lady [31]. The
pathogenesis of this is not fully understood but it has
been suggested it is due to an increase in Fas-antigen
mediated apoptosis of thyrocytes [32] and upregulation
of various cell surface markers implicated in auto-
immune disease (intercellular adhesion molecule-1,
Table 4 Literature Review
Author Where Year Diagnosed 1st Time between diagnosis Antibodies Sex Age Treatment
Aria N [3] Japan 2016 Simultaneous NA Positive F 40 CBZ- > TSS
Okyucu K [4] Turkey 2016 Simultaneous NA Positive F 37 PTU - > Thyroidectomy- > TSS
Ogawa Y [5] Japan 2013 GD 2 years Positive F 32 PTU- > TSS
Koriyama N [6] Japan 2004 TSHoma 3 years Negative F 37 Octreotide- > TSS - > CBZ
Kamoi K [7] Japan 1985 TSHoma 10 months Positive F 46 MMI- > TSS- > MMI
Kamoun M [8] France 2014 GD 2 years Positive F 36 CBZ - > Thyroidectomy - > TSS
Sandler R [9] US 1976 TSHoma 2 years Negative F 53 CBZ- > Pituitary radiotherapy - > PTU- > 131I
O’Donnell J [10] N.Ireland 1973 TSHoma 2months Negative M 25 CBZ - > Hypophysectomy - > CBZ
Lee MT [11] Taiwan 2010 GD 2 years Positive M 27 CBZ
Lee MT [11] Taiwan 2010 GD 6months Positive F 28 PTU
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major histocompatibility complex II) [9] in response to a
sudden fall in TSH levels.
Current guidelines for the treatment of a TSHoma rec-
ommend surgery as first line [33]. In our case the patient
declined this approach. Second line therapy in the form
of SSAs was then put in place. She did not tolerate this
so cabergoline was tried. Again, she failed to tolerate
this. Going forward we have decided to treat this lesion
conservatively with a beta-adrenergic blocker especially
as she was clinically euthyroid. Beta-blockers were con-
tinued to protect against the cardiac effects of her bio-
chemical thyrotoxicosis. We also used Denosumab to
treat her osteoporosis. She remains well on this regime
and attends our department for regular follow up.
Summary
This case highlights the need to consider a diagnosis of
a TSHoma when faced with discordant thyroid function
tests. It also highlights the specific diagnostic and thera-
peutic challenges associated with the metachronous
diagnoses of primary and central thyrotoxicosis in the
same patient. We have used this case to discuss the
current diagnostic tools at our disposal for the investiga-
tion of thyrotoxicosis. In addition, this case highlights
the utility of an 11C-methionine PET/CT scan coregis-
tered with volumetric MRI in the diagnosis of functional
endocrine tumours especially in cases of diagnostic un-
certainty. The limitations of this case report include the
lack of TSH receptor antibody levels, the lack of IPSS
and the lack of a confirmatory histological diagnosis.
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